These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35895101)

  • 1. Anticoagulation strategies and recurrence of venous thromboembolic events in patients with sickle cell disease: a systematic review and meta-analysis.
    El-Amin N; Iness A; Cyrus JW; Sisler I; Karam O
    Ann Hematol; 2022 Sep; 101(9):1931-1940. PubMed ID: 35895101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High incidence of venous thromboembolism recurrence in patients with sickle cell disease.
    Brunson A; Keegan T; Mahajan A; White R; Wun T
    Am J Hematol; 2019 Aug; 94(8):862-870. PubMed ID: 31074115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of oral anticoagulants in patients with sickle cell disease and venous thromboembolism: a retrospective cohort study.
    Roberts MZ; Gaskill GE; Kanter-Washko J; Kyle TR; Jones BC; Bohm NM
    J Thromb Thrombolysis; 2018 May; 45(4):512-515. PubMed ID: 29556958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased Bleeding Incidence with Direct Oral Anticoagulants Compared to Vitamin K Antagonist and Low-Molecular-Weight Heparin in Patients with Sickle Cell Disease and Venous Thromboembolism.
    Patel A; Williams H; Baer MR; Zimrin AB; Law JY
    Acta Haematol; 2019; 142(4):233-238. PubMed ID: 31108496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Direct Oral Anticoagulants in Patients with Sickle Cell Disease and Venous Thromboembolism: A Prospective Cohort Study of 12 Patients.
    Christen JR; Bertolino J; Jean E; Camoin L; Ebbo M; Harlé JR; Schleinitz N; Sarlon G; Bernit E
    Hemoglobin; 2019; 43(4-5):296-299. PubMed ID: 31724442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming challenges of venous thromboembolism in sickle cell disease treatment.
    Ogunsile FJ; Naik R; Lanzkron S
    Expert Rev Hematol; 2019 Mar; 12(3):173-182. PubMed ID: 30773073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
    Robertson L; Strachan J
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD006771. PubMed ID: 28195640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of rivaroxaban in sickle cell disease and venous thromboembolism: A case report.
    Rozi W; Ali EAH; Al-Mashdali AF; Abdelrazek M; Yassin MA
    Medicine (Baltimore); 2021 Dec; 100(51):e27988. PubMed ID: 34941038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Editor's Choice - A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer.
    Kirkilesis GI; Kakkos SK; Tsolakis IA
    Eur J Vasc Endovasc Surg; 2019 May; 57(5):685-701. PubMed ID: 31097186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know.
    Naik RP; Streiff MB; Lanzkron S
    J Thromb Thrombolysis; 2013 Apr; 35(3):352-8. PubMed ID: 23435703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venous thromboembolism in centenarians: Findings from the RIETE registry.
    Lacruz B; Tiberio G; Núñez MJ; López-Jiménez L; Riera-Mestre A; Tiraferri E; Verhamme P; Mazzolai L; González J; Monreal M;
    Eur J Intern Med; 2016 Dec; 36():62-66. PubMed ID: 27495947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How I diagnose and treat venous thromboembolism in sickle cell disease.
    Shet AS; Wun T
    Blood; 2018 Oct; 132(17):1761-1769. PubMed ID: 29764840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased incidence of VTE in sickle cell disease patients: risk factors, recurrence and impact on mortality.
    Brunson A; Lei A; Rosenberg AS; White RH; Keegan T; Wun T
    Br J Haematol; 2017 Jul; 178(2):319-326. PubMed ID: 28369826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venous thromboembolism in pregnancy.
    James AH
    Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):326-31. PubMed ID: 19228606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bleeding and thrombotic complications during treatment with direct oral anticoagulants or vitamin K antagonists in venous thromboembolic patients included in the prospective, observational START2-register.
    Palareti G; Antonucci E; Legnani C; Mastroiacovo D; Poli D; Prandoni P; Tosetto A; Pengo V; Testa S; Ageno W;
    BMJ Open; 2020 Nov; 10(11):e040449. PubMed ID: 33247017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamics of case-fatalilty rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism.
    Lecumberri R; Alfonso A; Jiménez D; Fernández Capitán C; Prandoni P; Wells PS; Vidal G; Barillari G; Monreal M;
    Thromb Haemost; 2013 Oct; 110(4):834-43. PubMed ID: 23846721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cohort Study on the Management of Cancer-Associated Venous Thromboembolism Aimed at the Safety of Stopping Anticoagulant Therapy in Patients Cured of Cancer.
    van der Hulle T; den Exter PL; van den Hoven P; van der Hoeven JJ; van der Meer FJ; Eikenboom J; Huisman MV; Klok FA
    Chest; 2016 May; 149(5):1245-51. PubMed ID: 26836911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of rivaroxaban for the prevention of thrombosis following total hip or knee replacement: A systematic review and meta-analysis.
    Liu J; Zhao J; Yan Y; Su J
    Medicine (Baltimore); 2019 Mar; 98(9):e14539. PubMed ID: 30817570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of DVT: how long is enough and how do you predict recurrence.
    Agnelli G; Becattini C
    J Thromb Thrombolysis; 2008 Feb; 25(1):37-44. PubMed ID: 17906973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.